Long-term improvement of quality of life during Growth Hormone (GH) replacement therapy in adults with GH deficiency, as measured by Questions on Life Satisfaction-Hypopituitarism (QLS-H)

Myriam Rosilio, Werner F. Blum, David J. Edwards, Elena P. Shavrikova, Domenico Valle, Steven W.J. Lamberts, Eva Marie Erfurth, Susan M. Webb, Richard J. Ross, Kazuo Chihara, Gerhard Henrich, Peter Herschbach, Andrea F. Attanasio

Research output: Contribution to journalArticleResearchpeer-review

100 Citations (Scopus)

Abstract

Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term GH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with GH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in GH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P = 0.006) and in adult-onset vs. childhood-onset GHD (P = 0.002). Multivariate analysis associated female gender, multiple pituitary hormone deficiencies, low serum IGF-I values (<75 μg/liter), and concomitant antidepressant medication with low baseline Z-scores. QLS-H Z-scores increased from -1.02 ± 1.43 (SD) at baseline to -0.25 ± 1.34 (SD) after 1 yr of GH treatment (P < 0.001) and were no longer significantly different from the general population after 4 yr of treatment. There was no correlation between change in Z-score and GH dose or changes in IGF-I and IGF binding protein-3 during treatment. This study demonstrates that 1) improvements in QoL, as measured by the QLS-H, are maintained during long-term GH replacement therapy of adults with GHD, and 2) the QLS-H is a useful tool for evaluating QoL in hypopituitary patients treated in clinical practice. The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult GH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points.
Original languageEnglish
Pages (from-to)1684-1693
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
DOIs
Publication statusPublished - 1 Apr 2004

Fingerprint Dive into the research topics of 'Long-term improvement of quality of life during Growth Hormone (GH) replacement therapy in adults with GH deficiency, as measured by Questions on Life Satisfaction-Hypopituitarism (QLS-H)'. Together they form a unique fingerprint.

Cite this